Non-fermented osmotic laxative and method for treating and preventing colorectal cancers

• US 6,939,563 B2
• Filed: 04/18/2001
• Issued: 09/06/2005
• Est. Priority Date: 10/27/1998
• Status: Expired due to Fees

• Current Assignee: Norgine B.V.
• Original Assignee: Envt-Ecole Nationale Veterinaire De Toulouse, Inra-Institut National de La Recherche Agronomique
• Inventors: Parnaud, Géraldine, Tache, Sylviane, Corpet, Denis
• Primary Examiner(s): Spear, James M.
• Assistant Examiner(s): CHANNAVAJJALA, LAKSHMI SARADA
• Application Number:
  US09/836,971
• Publication Number:
  US 20010051659A1
• Time in Patent Office: 1,602 Days
• Field of Search: 424/400, 424/489, 424/432, 424/436, 424/78.08, 424/78.19, 514/892
• US Class Current: 424/489
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/77 of oxiranes
• CPC Class Codes: A61P 1/10 Laxatives
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Use of a non-fermented osmotic laxative as an active agent for preparation of a medicinal product for treating and/or preventing colon and/or rectum cancers. A method of treating or preventing colon or rectum cancer comprising administering to a mammal a therapeutically effective amount of a non-fermented osmotic laxative.

Claims

1. A method of treating colon or rectum cancer comprising administering to a mammal a therapeutically effective amount of a non-fermented osmotic polyol laxative.

2. The method of claim 1, wherein the non-fermented osmotic laxative is polyethylene glycol or polyethylenepolypropylene glycol, a mixture or a derivative thereof.

3. The method of claim 2, wherein the polyethylene glycol or the derivative thereof has a molecular weight of more than approximately 400, and has a high molecular weight of about 3000 to about 9000 daltons.

4. The method of claim 2, wherein the polyethylene glycol or the derivative thereof has a molecular weight of more than approximately 1000, and has a high molecular weight of about 3000 to about 9000 daltons.

5. The method of claim 2, wherein the polyethylene glycol or the derivative thereof has a molecular weight of more than approximately 400, and has a high molecular weight of about 8000 daltons.

11. The method of claim 1, wherein said mammal is selected from the group consisting of persons genetically suffering from familial polyposis or Lynch'"'"'s syndrome, elderly persons and persons carrying risk factors.

6. A method of preventing colon or rectum cancer comprising administering to a mammal a therapeutically effective amount of a non-fermented osmotic polyol laxative.

7. The method of claim 6, wherein the non-fermented osmotic laxative is polyethylene glycol or polyethylenepolypropylene glycol, a mixture or a derivative thereof.

8. The method of claim 7, wherein the polyethylene glycol or the derivative thereof has a molecular weight of more than approximately 400, and has a high molecular weight of about 3000 to about 9000 daltons.

9. The method of claim 7, wherein the polyethylene glycol or the derivative thereof has a molecular weight of more than approximately 1000, and has a high molecular weight of about 3000 to about 9000 daltons.

10. The method of claim 7, wherein the polyethylene glycol or the derivative thereof has a molecular weight of more than approximately 400, and has a high molecular weight of about 8000 daltons.

12. The method of claim 6, wherein said mammal is selected from the group consisting of persons genetically suffering from familial polyposis or Lynch'"'"'s syndrome, elderly persons carrying risk factors.